Learning Objectives:
1. To review the current data on the risk of cardiovascular disease associated with tofacitinib
2. To learn about the new data about tofacitinib based on this study and how it could be applied to the clinical setting
Session date:
03/21/2023 - 9:30am to 10:30am CDT
Add to calendar:
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Participation
Speaker Name:
Kichul Ko, M.D.